TaylorMade Could Have a New Owner Soon
Centroid Investment Partners, the South Korean private equity firm that acquired TaylorMade in 2021, has begun the process of selling its stake in the brand. The Korean Economic Daily first reported the news. And while details remain limited, the move reflects strong investor interest as golf continues to ride a post-pandemic wave. TaylorMade has undoubtedly capitalized on this momentum in years, matching its expertise in drivers and fairways woods alongside sharp branding and tongue-in-cheek campaigns (remember that Christmas shoot?).
Since Centroid's acquisition, TaylorMade has grown steadily, posting an average annual growth rate of over 10% in net sales and more than 15% in EBITDA (earnings before interest, taxes, depreciation, and amortization), according to reports. The company has also expanded its influence, launching theSun Day Redapparel line alongsideTiger Woodsearlier this year and continuing to be the club of choice for some of the top players in the world like Scheffler, McIlroy, Korda and Collin Morikawa.
With its mix of elite performance, cultural relevance and global momentum, TaylorMade remains one of the most desirable brands in golf. Whether the ownership shifts behind the scenes or not, the company's trajectory or public facing image show no sign of changing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
3 hours ago
- UPI
South Korea's Samsung Biologics, Celltrion log stellar performances
1 of 2 | South Korean biopharmaceutical contract manufacturer Samsung Biologics posted a stellar performance in the first half of this year. Photo courtesy of Samsung Biologics SEOUL, July 24 (UPI) -- The South Korean economy struggles as the country's gross domestic product growth rate is feared to more than halve to less than 1% this year, compared to 2% for 2024. However, its defense and shipbuilding industries are faring well. Also among the high achievers are biopharmaceutical contract manufacturers, including Samsung Biologics and Celltrion. Samsung Biologics, one of the world's largest contract development and manufacturing organizations, or CDMOs, announced Wednesday that it posted record-high $1.88 billion in sales during the first six months of 2025, up 21.3% from a year earlier. Its operating profit amounted to $700 million, up 46.75%. The company also said that it has signed contracts worth $2.4 billion in the first half of the year, which is more than 60% of its total annual order volume for 2024. "As global demand for CDMO services continues to rise, we are rapidly expanding our production capacity," Samsung Biologics said in a statement. "Backed by our world-class CDMO capabilities, we plan to intensify our efforts to win more orders, particularly targeting the world's top 40 pharmaceutical companies." Samsung's local rival, Celltrion, is likewise seeing impressive results. The outfit announced Tuesday that its first-half turnover stood at $1.31 billion, up 11.9% year-on-year. Its operating income more than tripled to $285 million. The company's sales for this year are expected to top $3 billion for the first time, and its bottom line is projected to near the $1 billion mark. Observers have positive outlooks for the two powerhouses. "Samsung Biologics is beefing up its global competitiveness through the second campus, which includes plants five to eight," KB Securities researcher Kim Hye-min said in a market report. "The company is also expanding its capabilities beyond traditional monoclonal antibody-focused CDMO services to next-generation modalities and pre-filled syringes," she noted. Prefilled syringe manufacturing means that Samsung Biologics rolls out drugs in ready-to-inject formats. Global pharmaceutical clients tend to request this for chronic diseases or biologic treatments. Regarding Celltrion, Heungkuk Securities analyst Lee Ji-won said in a recent report that this year would be a pivotal point for the company's profit growth momentum. "Celltrion is predicted to demonstrate a significant year-on-year increase in profits, driven by the solid performance of newly launched high-margin biosimilars," Lee said. Experts said the CDMO businessm which is based on outsourced manufacturing, is an area in which Korean companies have advantages. "Although the Korean economy languishes due to various reasons this year, the biopharmaceutical outsourcing business is likely to rack up stellar performances for the time being. Samsung Biologics and Celltrion will spearhead the trend," Seoul-based business tracker Leaders Index CEO Park Ju-gun told UPI. "Samsung Biologics has already become an established player in the market, favored by global biopharmaceutical giants thanks to its cost competitiveness and quick delivery. Celltrion is also trying hard to become a big name in the market," he said. Economic analyst Kim Joon-Kyung, formerly vice chairman at Deloitte Consulting Korea, agreed. "First of all, the CDMO industry is promising. And from the perspective of Samsung, the business shares many characteristics with semiconductor production. Hence, the group had a good reason to tap into the CDMO sector," Kim said in a phone interview. "Celltrion did not have such advantages. But the company secured technological edges early on, which is quite an achievement. That's why Celltrion is showing solid performances now," he said. Samsung Electronics, the mother company of Samsung Biologics, is the world's largest maker of memory chips. According to U.S. market intelligence firm BCC Research, the global CDMO market is expected to expand to $191.6 billion by 2029 from $136.6 billion last year based on mounting demand for outsourced drug development and manufacturing. Other biopharmaceutical companies in Korea also are striving to tap into the lucrative CDMO business, including SK Bioscience and Lotte Biologics. Toward that end, SK Bioscience acquired a controlling stake in IDT Biologika of Germany, which is one of the top 10 global vaccine CDMOs, late last year. Lotte Biologics has launched operations of its antibody-drug conjugate facility at its Syracuse Bio Campus in the United States. The company also is preparing its first plant located just west of Seoul, aiming to begin commercial production in 2027.
Miami Herald
5 hours ago
- Miami Herald
Hyundai Beats Q2 Forecasts Thanks to Strong U.S. Sales and Hybrid Demand
Hyundai Motor Company has announced its business results for the second quarter. Like all automakers, the Korean brand's performance is under increased scrutiny in light of the challenges created by tariffs. The brand's second-quarter revenue reached a record KRW 48.29 trillion (South Korean won), which translates to roughly $35.3 billion. This amounts to a year-on-year increase of 7.3%. However, the company's operating profit dropped by 15.8% year-on-year to KRW 3.6 trillion (approx. $2.62 billion); this just about beat estimates of KRW 3.5 trillion (approx. $2.55 billion). Strong demand in the North American market, along with the popularity of hybrid models, helped Hyundai navigate a tough environment in Q2. Between April and June 2025, Hyundai sold a total of 1,065,836 units globally, a 0.8% increase over the same period last year. Outside of Korea, sales were up by 0.7%, but North American sales growth stood out, rising by 3.3% over this period. The Tucson, Sante Fe, and Elantra all performed strongly for the brand. Previously, we reported on strong first-half sales for Hyundai in the United States, boosted by a rise in electrified vehicle sales. Globally, sales of electrified Hyundais increased to over 262,000 units, an increase of 36.4%. Hybrid sales in Q2 hit 168,703 units globally, a record figure that represents a 38.5% increase over the same period in 2024. Operating profit was already down in Q2, but the current 25% tariff on Korean vehicles is expected to be felt more severely in the current quarter. That's because Hyundai Motor front-loaded shipments to reduce the blow of tariffs, but this inventory is now drying up, reports Reuters. Instead of increasing prices like many other automakers, Hyundai absorbed the higher costs associated with tariffs, saying it will adjust prices of vehicles in the U.S. based on market conditions and competitors, rather than tariffs. However, Hyundai is expected to soon find itself at a disadvantage when compared to Japanese automakers. Trump's new trade deal with Japan will reduce tariffs for brands like Toyota and Honda, giving them a competitive advantage. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
USA Today
5 hours ago
- USA Today
Scottie Scheffler installed as favorite for all 2026 majors, including the Masters
In one of the most honest and introspective moments of the 2025 pro gold season, world No. 1 Scottie Scheffler gave one of the most revealing answers of the year during his press conference ahead of the 153rd British Open in what turned into a therapy session of sorts for him. Scheffler insisted that he sometimes wondered what the point of his golf obsession was — and then he went out and dominated the field to capture his fourth major championship. With the major season now in the rearview mirror, it's time to look ahead to 2026 and, according to Vegas oddsmakers, those scheduling tournaments might be the ones asking, "What's the point?" According to BetMGM, Scheffler is the favorite to win each of golf's four majors next year, which was also the case in 2025, when he did capture half of the world's most prized trophies. Scheffler captured the PGA Championship in May, meaning he only needs a U.S. Open to complete a career Grand Slam. The only others in the modern era to pull off that trick are Gene Sarazen, Ben Hogan, Gary Player, Jack Nicklaus, Tiger Woods and Rory McIlroy.'Any doubts about Scottie Scheffler's British Open pedigree were emphatically squashed by the American at Royal Portrush with an effortless four-shot victory," BetMGM senior trader Matt Wall told USA Today Sports. "BetMGM immediately shortened his 2026 Masters price to +400 from +500 and that could still shorten further should he continue to dominate on the PGA Tour. The comparisons with Tiger Woods certainly don't look out of place right now. All the early action is on Scottie to win all four majors at +25000, and he is the favorite in each one right now.' Here's a look at the early odds to win golf's majors in 2026:BetMGM odds as of July 22 The Masters 2026 odds Scottie Scheffler: +400Rory McIlroy: +550Ludvig Aberg: +1200Bryson DeChambeau: +1400Collin Morikawa: +1400Jon Rahm: +1400Xander Schauffele: +1600Justin Thomas: +2500Brooks Koepka: +2800Viktor Hovland: +2800 PGA Championship 2026 odds Scottie Scheffler: +400Rory McIlroy: +600Bryson DeChambeau: +800Jon Rahm: +1400Xander Schauffele: +1600Collin Morikawa: +2000Justin Thomas: +2000Ludvig Aberg: +2200 U.S. Open 2026 odds Scottie Scheffler: +400Bryson DeChambeau: +800Rory McIlroy: +900Jon Rahm: +1200Xander Schauffele: +1800Ludvig Aberg: +2000Collin Morikawa: +2500Justin Thomas: +3300Tyrrell Hatton: +3300Viktor Hovland: +3300 The Open Championship odds Scottie Scheffler: +400Rory McIlroy: +900Jon Rahm: +1200Bryson DeChambeau: +1600Xander Schauffele: +1800Ludvig Aberg: +2200Tommy Fleetwood: +2500Tyrrell Hatton: +2500Robert MacIntyre: +2800Viktor Hovland: +2800Gambling involves risk. Please only gamble with funds that you can comfortably afford to lose. While we do our utmost to offer good advice and information we cannot be held responsible for any loss that may be incurred as a result of gambling. We do our best to make sure all the information that we provide on this site is correct. However, from time to time mistakes will be made and we will not be held liable. Please check any stats or information if you are unsure how accurate they are. No guarantees are made with regards to results or financial gain. All forms of betting carry financial risk and it is up to the individual to make bets with or without the assistance of information provided on this site and we cannot be held responsible for any loss that may be incurred as a result of following the betting tips provided on this site. Past performances do not guarantee success in the future and betting odds fluctuate from one minute to the next. The material contained on this site is intended to inform, entertain and educate the reader and in no way represents an inducement to gamble legally or illegally or any sort of professional may earn revenue from sports betting operators for audience referrals to betting services. Sports betting operators have no influence over nor are any such revenues in any way dependent on or linked to the newsrooms or news coverage. Terms apply, see operator site for Terms and Conditions. If you or someone you know has a gambling problem, help is available. Call the National Council on Problem Gambling 24/7 at 1-800-GAMBLER (NJ, OH), 1-800-522-4700 (CO), 1-800-BETS-OFF (IA), 1-800-9-WITH-IT (IN). Must be 21 or older to gamble. Sports betting and gambling are not legal in all locations. Be sure to comply with laws applicable where you reside. It is your sole responsibility to act in accordance with your local laws.
